Sphingosine kinases signalling in carcinogenesis

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 4, 2015, Pages 300-314

  Marfe, Gabriella ^a   Mirone, Giovanna ^b   Shukla, Arvind ^c   di Stefano, Carla ^d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c D Y PATIL UNIVERSITY   (India)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cancer; Receptor tyrosine kinases (RTKs); Sphingolipids; Sphingosine 1 phosphate (S1P); Sphingosine kinase 1 (SphK1); Tyrosine kinase inibitors (TKIs)

Indexed keywords

3 (4 CHLOROPHENYL) N (4 PYRIDINYLMETHYL) ADAMANTANE 1 CARBOXAMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYCLIN D1; DOXORUBICIN; FINGOLIMOD; IMATINIB; IMMUNOMODULATING AGENT; INTERLEUKIN 3; N, N DIMETHYLSPHINGOSINE; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SLP 120701; SLR 08081; SORAFENIB; SPHINGOLIPID; SPHINGOMAB; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; SPHINGOSINE KINASE 2; SPHINGOSINE KINASE INHIBITOR; THREODIHYDROSPHINGOSINE; UNCLASSIFIED DRUG; PHOSPHOTRANSFERASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG RESISTANCE; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; GENE; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; MANTLE CELL LYMPHOMA; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; POSITIVE FEEDBACK; PROTEIN EXRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; ENZYMOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; CARCINOGENESIS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 84930974989     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150227105415     Document Type: Article

References (211)

1. Dickson, R. C. Sphingolipid functions in Saccharomyces cerevisiae: comparision mammals. Ann. Rev. Biochem., 1998, 67, 27-48.
2. Contreras, F. X.; Basanez, G.; Alonso, A.; Herrmann. A.; Goni, F. M. Asymmetric addition of ceramides but not dihydroceramides promotes transbilayer(flip-flop) lipid motion in membranes. Biophy. J., 2005, 88(1), 348-359.
3. van Meer, G.; Lisman, Q. Sphingolipid transport: rafts and translocators. J. Biol. Chem., 2002; 277(29), 25855-25858.
4. Hakomori, S.; Igarashi, Y. Functional role of glycosphingolipids in cell recognition and signaling. J. Biochem., 1995, 118(6), 1091-1103.
5. Degroote, S.; Wolthoorn, J.; van Meer, G. The cell biology of glycosphingolipids. Semin. Cell Dev. Biol., 2004, 15(4), 375-387.
6. Lopez-Montero, I.; Rodriguez, N.; Cribier, S.; Pohl, A.; Velez, M.; Devaux, P. F. Rapid transbilayer movement of ceramides in phospholipid vesicles and in human erythrocytes. J. Biol. Chem., 2005, 280(27), 25811-25819.
7. Marchesini, N.; Hannun, Y. A. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem. Cell Biol., 2004, 82(2), 27-44.
8. Hait, N. C.; Oskeritzian, C. A.; Paugh, S. W.; Milstien, S.; Spiegel S. Sphingosine kinases, sphingosine 1 phosphate, apoptosis and diseases. Biochim. Biophys. Acta., 2006, 1758(12), 2016-2026.
9. Furuya, S.; Mitoma, J.; Makino, A.; Hirabayashi, Y. Ceramide and its interconvertible metabolite sphingosine function as indispensable lipid factors involved in survival and dendritic differentiation of cerebellar Purkinje cells. J. Neurochem., 1998, 71(1), 366-377.
10. Cuvillier, O. Sphingosine in apoptosis signaling. Biochim. Biophys. Acta, 2002, 1585(2-3), 153-162.
11. Kagedal, K.; Zhao, M.; Svensson, I.; Brunk, UT. Sphingosineinduced apoptosis is dependent on lysosomal proteases. Biochem. J., 2001, 359, 335-343.
12. Karliner, J. S. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim. Biophys. Acta, 2013, 1831(1), 203-212.
13. Pitson, S. M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci., 2011, 36(2), 97-107.
14. Taha, T. A.; Hannun, Y. A.; Obeid, L. M. Sphingosine kinase: biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol., 2006, 39(2), 113-131.
15. Venkataraman, K.; Thangada, S.; Michaud, J.; Lo, M. L.; Ai, Y.; Lee, Y. M.; Wu, M.; Parikh, N. S.; Khan, F.; Proia, R. L.; Hla, T. Extracellular export of sphingosine kinase-l a contributes to the vascular SIP gradient. Biochem. J., 2006, 397(3), 461-471.
16. Hammad, S. M.; Taha, T. A.; Nareika, A.; Johnson, K. R.; Lopes-Virella, M. F.; Obeid, L. M. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins and other Lipid Mediators, 2006, 79(1-2), 126-140.
17. Pyne, S.; Pyne, N. J. Sphingosine I-phosphate signalling in mammalian cells. Biochem. J., 2000, 349(Pt. 2), 385-402.
18. Kon, J.; Sato, K.; Watanabe, T.; Tomura, H.; Kuwabara, A.; Kimura, T.; Tamama, K.; Ishizuka, T.; Murata, N.; Kanda, T.; Kobayashi, I.; Ohta, H.; Ui, M.; Okajima, F. Comparison of intrinsic activities of the putative sphingosine I-phosphate receptor subtypes to regulate several signaling pathways in their cDNAtransfected Chinese hamster ovary cells. J. Biol. Chem., 1999, 274(34), 23940-23947.
19. Liu, Y.; Wada, R.; Yamashita, T.; Mi, Y.: Deng, C. X.; Hobson, J. P.; Rosenfeldt, H. M.; Nava, V. E.; Chae, S. S.: Lee, M. J.; Liu, C. H.; Hla, T.; Spiegel, S. L. Edg-l, the G protein-coupled receptor for sphingosine-I-phosphate, is essential for vascular maturation. J. Clin. Inv., 2000, 106(8), 951-961.
20. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on SIP receptor 1. Nature, 2004, 427(6972), 355-360.
21. Lepley, D.; Paik, J. H.; Hla, T.; Ferrer, F. The G protein-coupled receptor SIP2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res., 2005, 65(9), 3788-3795.
22. Kono, M.; Mi, Y.; Liu, Y.; Sasaki, T.; Allende, M. L.; Wu, Y. P.; Yamashita, T.; Proia, R. L. The sphingosine-l-phosphate receptors SIPl, SIP2, and S1P3 function coordinately during embryonic angiogenesis. J. Biol. Chem., 2004, 279(28), 29367-29373.
23. Forrest, M.; Sun, S. Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G. J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S. Immune cell regulation and cardiovascular effects of sphingosine Iphosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther., 2004, 309(2), 758-768.
24. Graler, M. H.; Grosse, R.; Kusch, A.; Kremmer, E.; Gudermann, T.; Lipp, M. The sphingosine 1-phosphate receptor S 1 P4 regulates cell shape and motility via coupling to Gi and G 12/13. J. Cel. Biochem., 2003, 89(3), 507-519.
25. Wang, W.; Graeler, M. H.; Goetzl, E. J. Type 4 sphingosine Iphosphate G proteincoupled receptor (S1P4) transduces SIP effects on T cell proliferation and cytokine secretion without signaling migration. Faseb J., 2005, 19(12), 1731-1733.
26. Terai, K.; Soga, T.; Takahashi, M.; Kamohara, M.; Ohno, K.; Yatsugi, S.; Okada, M.; Yamaguchi, T. Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience, 2003, 116(4), 1053-1062.
27. Olivera, A.; Kohama, T.; Tu, Z.; Milstien, S.; Spiegel, S. Purification and characterization of rat kidney sphingosine kinase. J. Biol. Chem., 1998, 273(20), 12576-12583.
28. Kohama, T.; Olivera, A.; Edsall, L.; Nagiec, M. M.; Dickson, R.; Spiegel, S. Molecular cloning and functional characterization of murine sphingosine kinase. J. Biol. Chem., 1998, 273(37), 23722-23728.
29. Nava, V. E.; Lacana, E.; Poulton, S.; Liu, H.; Sugiura, M.; Kono, K.; Milstien, S.; Kohama, T.; Spiegel, S. Functional characterization of human sphingosine kinase-1. FEBS Lett., 2000, 473(1), 81-84.
30. Pitson, S. M.; Moretti, P. A.; Zebol, J. R.; Xia, P.; Gamble, J. R.; Vadas. M. A.; D'Andrea, R. J.; Wattenberg, B. W. Expression of a catalytically inactive sphingosine kinase mutant blocks agonistinduced sphingosine kinase activation. A dominant-negative sphingosine kinase. J. Biol. Chem., 2000, 275(43), 33945-33950.
31. French, K. J.; Schrecengost, R. S.; Lee, B. D.; Zhuang, Y.; Smith, S. N.; Eberly, J. L.; Yun J. K.; Smith, C. D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63(18), 5962-5969.
32. Spiegel, S.; Milstien, S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol., 2003, 4(5), 397-407.
33. Melendez, A. J.; Carlos-Dias, E.; Gosink, M.; Allen, J. M.; Takacs, L. Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene., 2000, 251(1), 19-26.
34. Karliner, J. S. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim. Biophys. Acta. 2013, 1831(1), 203-212.
35. Pitson, S. M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci., 2011, 36(2), 97-107.
36. Taha, T. A.; Hannun, Y. A.; Obeid, L. M. Sphingosine kinase: biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol., 2006, 39(2), 113-131.
37. Pitson, S. M.; Moretti, P. A.; Zebol, J. R.; Lynn, H. E.; Xia, P.; Vadas, M. A.; Wattenberg, B. W. Activation of sphingosine kinase 1 by ERKI/2-mediated phosphorylation. EMBO J., 2003, 22(20), 5491-5500.
38. Johnson, K. R.; Becker, K. P.; Facchinetti, M. M.; Hannun, Y. A.; Obeid, L. M. PKC dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-I-phosphate induced by phorbol 12-myristate 13-acetate(PMA). J. Biol. Chem., 2002, 277(38), 35257-35262.
39. Wallington-Beddoe, C. T.; Bradstock, K. F.; Bendall, L. J. Oncogenic properties of sphingosine kinases in haematological malignancies. Br. J. Haematol., 2013, 161(5), 623-638.
40. Sutherland, C. M.; Moretti, P. A.; Hewitt, N. M.; Bagley, C. J.; Vadas, M. A.; Pitson, S. M. The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane. J. Biol. Chem., 2006, 281(17), 11693-11701.
41. Hobson, J. P.; Rosenfeldt, H. M.; Barak, L. S.; Olivera, A.; Poulton, S.; Caron, M. G.; Milstien, S.; Spiegel, S. Role of the sphingosine-1-phosphate receptor EDG-l in PDGF-induced cell motility. Science, 2001, 291(5509), 1800-1803.
42. Shu, X.; Wu, W.; Mosteller, R. D.; Broek, D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation ofras and mitogen-activated protein kinases. Mol. Cellular Biol., 2002, 22(22), 7758-7768.
43. EI-Shewy, H. M.; Johnson, K. R.; Lee, M. H.; Jaffa, A. A.; Obeid, L. M.; Luttrell, L. M. Insulin like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by trans activating sphingosine 1-phosphate receptors. J. Biol. Chem., 2006, 281(42), 31399-31407.
44. Pyne, S.; Lee, S. C.; Long, J.; Pyne, N. J. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal, 2009, 21(1), 14-21.
45. Pitson, S. M.; Xia, P; Leclercq, T. M.; Moretti, P. A.; Zebol, J. R.; Lynn, H. E.; Wattenberg, B. W.; Vadas, M. A. Phosphorylationdependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med., 2005, 201(1), 49-54.
46. Barr, R. K.; Lynn, H. E.; Moretti, P. A.; Khew-Goodall, Y.; Pitson, S. M. Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J. Biol. Chem., 2008, 283(50), 34994-5002.
47. Griner, E. M.; Kazanietz, M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer, 2007, 7(4), 281-294.
48. Stahelin, R. V.; Hwang, J. H.; Kim, J. H.; Park, Z. Y.; Johnson, K. R.; Obeid, L. M.; Cho, W. The mechanism of membrane targeting of human sphingosine kinase 1. J. Biol. Chem., 2005, 280(52), 43030-43038.
49. Ding, G.; Sonoda, H.; Yu, H.; Kajimoto, T.; Goparaju, S. K.; Jahangeer, S; Okada, T.; Nakamura, S. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J Biol Chem., 2007, 282(37), 27493-27502.
50. Hait, N. C.; Allegood, J.; Maceyka, M.; Strub, G. M.; Harikumar, K. B.; Singh, S. K.; Marmorstein, R.; Kordula, T.; Milstien, S.; Spiegel, S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science, 2009, 325(5945), 1254-1257.
51. Igarashi, N.; Okada, T.; Hayashi, S., Fujita, T.; Jahangeer, S.; Nakamura, S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem., 2003, 278(43), 46832-46839.
52. Hait, N. C.; Sarkar, S.; Le Stunff, H.; Mikami, A.; Maceyka, M.; Milstien, S.; Spiegel, S. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J. Biol. Chem., 2005, 280(33), 29462-29469.
53. Hait, N. C.; Bellamy, A.; Milstien, S.; Kordula, T., Spiegel, S. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J. Biol. Chem., 2007, 282(16), 12058-12065.
54. Ding, G.; Sonoda, H.; Yu, H.; Kajimoto, T.; Goparaju, S. K.; Jahangeer, S; Okada, T.; Nakamura, S. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J. Biol. Chem., 2007, 282(37), 27493-27502.
55. Maceyka, M.; Sankala, H.; Hait, N. C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L. S.; Merrill, A. H. Jr.; Milstien, S.; Spiegel, S. SphKl and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 2005, 280(44), 37118-37129.
56. Zheng, W.; Kollmeyer, J.; Symolon, H.; Momin, A.; Munter, E.; Wang, E.; Kelly, S.; Allegood, J. C.; Liu, Y.; Peng, Q.; Ramaraju, H.; Sullards, M. C.; Cabot, M.; Merrill, A. H. Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta, 2006, 1758(12), 1864-1884.
57. Pruett, S. T.; Bushnev, A.; Hagedorn, K.; Adiga, M.; Haynes, C. A.; Sullards, M. C.; Liotta, D. C.; Merrill, A. H. Jr. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. J. Lipid Res., 2008, 49(8), 1621-1639.
58. Michel, C.; van Echten-Deckert, G.; Rother, J.; Sandhoff, K.; Wang, E.; Merrill, A. H. Jr. Characterization of ceramide synthesis A dihydroceramide desaturase introduces the 4, 5-trans-double bond of sphingosine at the level of dihydroceramide. J. Biol. Chem., 1997, 272(36), 22432-22437.
59. Ohotski, J.; Edwards, J.; Elsberger, B.; Watson, C.; Orange, C.; Mallon, E.; Pyne, S.; Pyne, N. J. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. Int. J. Cancer, 2013, 132(3), 605-616.
60. Ohotski, J.; Long, J. S.; Orange, C.; Elsberger, B.; Mallon, E.; Doughty, J.; Pyne, S.; Pyne, N. J.; Edwards, J. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer, 2012, 106(8), 1453-1459.
61. Zhang, W.; Zhao, J.; Lee, J. F.; Gartung, A.; Jawadi, H.; Lambiv, W. L.; Honn, K. V.; Lee, M. J. ETS-1-mediated transcriptional upregulation of CD44 is required for sphingosine-1-phosphate receptor subtype 3-stimulated chemotaxis. J. Biol. Chem., 2013, 288(45), 32126-3237.
62. Liang, J.; Nagahashi, M.; Kim, E. Y.; Harikumar, K. B.; Yamada, A.; Huang, W. C.; Hait, N. C.; Allegood, J. C.; Price, M. M.; Avni, D.; Takabe, K.; Kordula, T.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell, 2013, 23(1), 107-120.
63. Kawahara, S.; Otsuji, Y.; Nakamura, M.; Murakami, M.; Murate, T.: Matsunaga, T.; Kanoh, H.; Seishima, M.; Banno, Y.; Hara, A. Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells. Anticancer Drugs, 2013, 24(5), 473-483.
64. Huang, Y. L.; Chang, C. L.; Tang, C. H.; Lin, Y. C.; Ju, T. K.; Huang, W. P.; Lee, H. Extrinsic sphingosine 1-phosphate activates S1P5 and induces autophagy through generating endoplasmic reticulum stress in human prostate cancer PC-3 cells. Cell Signal., 2014, 26(3), 611-618.
65. Beckham, T. H.; Cheng, J. C.; Lu, P.; Marrison, S. T.; Norris, J. S.; Liu, X. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS One, 2013, 8(10), e76593.
66. Wang, C.; Mao, J.; Redfield, S.; Mo, Y., Lage, J. M.; Zhou, X. Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues. Exp. Mol. Pathol., 2014, 97(2), 259-265.
67. Don, A. S.; Lim, X. Y.; Couttas, T. A. Re-Configuration of Sphingolipid Metabolism by Oncogenic Transformation. Biomolecules, 2014, 4(1), 315-353.
68. Akao, Y.; Banno, Y.; Nakagawa, Y.; Hasegawa, N.; Kim, T. J.; Murate, T.; Igarashi, Y.; Nozawa, Y. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced upregulation. Biochem. Biophys. Res. Commun., 2006, 342(4), 1284-1290.
69. Kawamori, T.; Kaneshiro, T.; Okumura, M.; Maalouf, S.; Uflacker, A.; Bielawski, J.; Hannun, Y. A.; Obeid, L. M. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J., 2009, 23(2), 405-414.
70. Johnson, K. R.; Johnson, K. Y.; Crellin, H. G.; Ogretmen, B.; Boylan, A. M.; Harley, R. A.; Obeid, L. M. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J. Histochem. Cytochem., 2005, 53(9), 1159-1166.
71. Brizuela, L.; Ader, I.; Mazerolles, C.; Bocquet, M.; Malavaud, B.; Cuvillier, O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol. Cancer Ther., 2012, 11(9), 1841-1851.
72. Knapp, P.; Baranowski, M.; Knapp, M.; Zabielski, P.; Blachnio-Zabielska, A. U.; Górski, J. Altered sphingolipid metabolism in human endometrial cancer. Prostaglandins and other Lipid Mediators, 2010, 92(1-4), 62-66.
73. Malavaud, B.; Pchejetski, D.; Mazerolles C.; de Paiva, G. R.; Calvet, C.; Doumerc, N.; Pitson, S.; Rischmann, P.; Cuvillier, O. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur. J. Cancer, 2010, 46(18), 3417-3424.
74. Zhang, Y.; Wang, Y.; Wan, Z.; Liu, S.; Cao, Y.; Zeng, Z. Sphingosine Kinase 1 and Cancer: A Systematic Review and Meta-Analysis. PLoS One, 2014, 9(82), e90362.
75. Shida, D.; Takabe, K.; Kapitonov, D.; Milstien, S.; Spiegel, S. Targeting SphK1 as a New Strategy against Cancer. 2008, 9, 662-673.
76. Salas A.; Ponnusamy S.; Senkal C. E.; Meyers-Needham M.; Selvam S. P.; Saddoughi S. A.; Apohan E.; Sentelle R. D.; Smith C.; Gault C. R.; Obeid, L. M.; El-Shewy, H. M.; Oaks, J.; Santhanam, R.; Marcucci, G.; Baran, Y.; Mahajan, S.; Fernandes, D.; Stuart, R.; Perrotti, D.; Ogretmen, B. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood, 2011, 117(22), 5941-5952.
77. Kapitonov D.; Allegood J. C.; Mitchell C.; Hait N. C.; Almenara J. A.; Adams J. K.; Zipkin R. E.; Dent P.; Kordula T.; Milstien S.; Spiegel, S. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res., 2009, 69(17), 6915-6923.
78. Pchejetski D.; Golzio M.; Bonhoure E.; Calvet C.; Doumerc N.; Garcia V.; Mazerolles C.; Rischmann P.; Teissié J.; Malavaud B.; Cuvillier, O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res., 2005, 65(24), 11667-11675.
79. Doll F.; Pfeilschifter J.; Huwiler A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim. Biophys. Acta, 2005, 1738(1-3), 72-81.
80. Estrada-Bernal A.; Lawler S. E.; Nowicki M. O.; Ray Chaudhury A.; van Brocklyn J. R. The role of sphingosine kinase-1 in EGFRvIIIregulated growth and survival of glioblastoma cells. J. Neurooncol., 2010 102(3), 353-366.
81. Shida, D.; Kitayama, J.; Yamaguchi, H.; Yamashita, H.; Mori, K.; Watanabe, T.; Yatomi, Y.; Nagawa, H. Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor(EGFR) in human gastric cancer cells. FEBS Lett., 2004, 577(3), 333-338.
82. Baudhuin, L. M.; Jiang, Y.; Zaslavsky, A.; Ishii, I.; Chun, J.; Xu, Y. S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB J., 2004, 18(2), 341-343.
83. Endo, A.; Nagashima, K.; Kurose, H.; Mochizuki, S.; Matsuda, M.; Mochizuki, N. Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII. J. Biol. Chem., 2002, 277(26), 23747-23754.
84. Tanimoto, T.; Jin, Z. G.; Berk, B. C. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J. Biol. Chem., 2002, 277(45), 42997-43001.
85. Kohno, M.; Momoi, M.; Oo, M. L.; Paik, J. H.; Lee, Y. M.; Venkataraman, K.; Ai. Y.; Ristimaki, A. P.; Fyrst, H.; Sano, H.; Rosenberg, D.; Saba, J. D.; Proia, R. L.; Hla T. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol. Cell Biol., 2006, 26(199), 7211-7223.
86. Li Q. F.; Huang W. R.; Duan H. F.; Wang H.; Wu C. T.; Wang L. S. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene, 2007, 26(57), 7904-7908.
87. Albinet V.; Bats M. L.; Huwiler A.; Rochaix P.; Chevreau C.; Segui B.; Levade T.; Andrieu-Abadie N. Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells. Oncogene, 2014, 33(26), 3364-3373.
88. Gault, C. R.; Eblen, S. T.; Neumann, C. A.; Hannun, Y. A.; Obeid, L. M. Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-dependent manner. J. Biol. Chem., 2012, 287(38), 31794-31803.
89. Helke, K. L.; Jenkins, R. W.; de Costa, A. M.; Hannun, Y. A., Obeid, L. M. Defining a role for sphingosine kinase 1 in p53-dependent tumors. Oncogene, 2012, 31(9), 1166-1175.
90. Billich A.; Bornancin F.; Mechtcheriakova D.; Natt F., Huesken D.; Baumruker T. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: Function in cell survival and IL-1-beta and TNF-alpha induced production of inflammatory mediators. Cell. Signal., 2005, 17(10), 1203-1217.
91. Paugh, B. S.; Bryan, L.; Paugh, S. W.; Wilczynska, K. M.; Alvarez, S. M.; Singh, S. K.; Kapitonov, D.; Rokita, H.; Wright, S.; Griswold-Prenner, I.; Milstien, S.; Spiegel, S.; Kordula, T. Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J. Biol. Chem., 2009, 284(6), 3408-3417.
92. Xia, P.; Wang, L.; Moretti, P. A.; Albanese, N.; Chai, F.; Pitson, S. M.; D'Andrea, R. J.; Gamble, J. R.; Vadas, M. A. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factoralpha signaling. J. Biol. Chem., 2002, 277(10), 7996-8003.
93. Anelli, V.; Gault, C. R.; Cheng, A. B.; Obeid, L. M. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J. Biol. Chem., 2008, 283(6), 3365-3375.
94. Ader, I.; Brizuela, L.; Bouquerel, P.; Malavaud, B.; Cuvillier, O. Sphingosine kinase 1: A new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res., 2008, 68(20), 8635-8642.
95. Cuvillier O.; Pirianov G.; Kleuser B.; Vanek P. G.; Coso O. A.; Gutkind S.; Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 1996, 381(6585), 800-803.
96. Sorensen, S. D.; Nicole, O.; Peavy, R. D.; Montoya, L. M.; Lee, C. J.; Murphy, T. J.; Traynelis, S. F.; Hepler, J. R. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol. Pharmacol., 2003, 64(5), 1199-1209.
97. Miller, A. V.; Alvarez, S. E.; Spiegel, S.; Lebman, D. A. Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. Mol. Cell. Biol., 2008, 28(12), 4142-4151.
98. Shirai, K.; Kaneshiro, T.; Wada, M., Furuya, H.; Bielawski, J.; Hannun, Y. A.; Obeid, L. M.; Ogretmen, B.; Kawamori, T. A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer Prev. Res., 2011, 4(3), 454-462.
99. Guan, H.; Song, L.; Cai, J.; Huang, Y.; Wu, J.; Yuan, J.; Li, J.; Li, M. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS One, 2011, 6(5), e19946.
100. Takuwa, N.; Du, W.; Kaneko, E.; Okamoto, Y.; Yoshioka, K.; Takuwa, Y. Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1-Jekyll Hidden behind Hyde Am. J. Cancer Res., 2011, 1(14), 460-481.
101. Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.; Forman, S.; Jove, R.; Yu, H. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med., 2010, 16(12), 1421-1428.
102. Van Brocklyn J. R.; Jackson C. A.; Pearl D. K.; Kotur M. S.; Snyder P. J.; Prior T. W. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J. Neuropathol. Exp. Neurol., 2005, 64(8), 695-705.
103. Yoshida, Y.; Nakada, M.; Harada, T.; Tanaka, S.; Furuta, T.; Hayashi, Y.; Kita, D.; Uchiyama, N.; Hayashi, Y.; Hamada, J. The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J. Neurooncol., 2010, 98(1), 41-47.
104. Yoshida, Y.; Nakada, M.; Sugimoto, N.; Harada, T.; Hayashi, Y.; Kita, D.; Uchiyama, N.; Hayashi, Y.; Yachie, A.; Takuwa, Y.; Hamada, J. Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int. J. Cancer., 2010, 126(10), 2341-2352.
105. Pham, D. H.; Powell, J. A.; Gliddon, B. L.; Moretti, P. A.; Tsykin, A.; Van der Hoek, M.; Kenyon, R.; Goodall, G. J.; Pitson, S. M. Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1. Oncogene, 2014, 33(48), 5559-5568.
106. Bianchi, L.; Tacchini, L.; Cairo, G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res., 1999, 27(21), 4223-4227.
107. Ader, I.; Malavaud, B.; Cuvillier, O. When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res., 2009, 69(9), 3723-3726.
108. Michaud, M. D.; Robitaille, G. A.; Gratton, J. P.; Richard, D. E. Sphingosine-1-phosphate: a novel nonhypoxic activator of hypoxia-inducible factor-1 in vascular cells. Arterioscler. Thromb. Vasc. Biol., 2009, 29(6), 902-908.
109. Pchejetski, D.; Nunes, J.; Coughlan, K.; Lall, H., Pitson, S. M.; Waxman, J.; Sumbayev, V. V. The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4 mediated accumulation of HIF-1α protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol. Cell Biol., 2011, 89(2), 268-274.
110. Liu, H.; Toman, R. E.; Goparaju, S. K.; Maceyka, M.; Nava, V. E.; Sankala, H.; Payne, S. G.; Bektas, M.; Ishii, I.; Chun, J.; Milstien, S.; Spiegel, S. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J. Biol. Chem., 2003, 278(41), 40330-40336.
111. Liu, H.; Sugiura, M.; Nava, V. E.; Edsall, L. C.; Kono, K.; Poulton, S.; Milstien, S.; Kohama. T.; Spiegel, S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem., 2000, 275(26), 19513-19520.
112. Sankala, H. M.; Hait, N. C.; Paugh, S. W.; Shida, D.; Lepine, S.; Elmore. L. W.; Milstien, S.; Spiegel, S. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res., 2007, 67(21), 10466-10474.
113. Gao, P.; Smith, C. D. Ablation of Sphingosine Kinase-2 Inhibits Tumor Cell Proliferation and Migration. Mol. Cancer Res., 2011, 9(11), 1509-1519.
114. Kummetha Venkata, J.; An, N.; Stuart, R.; Costa, L. J.; Cai, H.; Coker, W.; Song. J. H.; Gibbs, K.; Matson, T.; Garrett-Mayer, E.; Wan, Z.; Ogretmen, B.; Smith, C.; Kang, Y. Inhibition of sphingosine kinase 2 down-regulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood, 2014, 124(12), 1915-1925.
115. Weigert, A.; Schiffmann, S.; Sekar, D.; Ley, S.; Menrad, H.; Werno, C.; Grosch, S.; Geisslinger, G.; Brüne, B. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Intl. J. Cancer, 2009, 125(9), 2114-2121.
116. Hofmann, L. P.; Ren, S.; Schwalm, S.; Pfeilschifter, J.; Huwiler, A. Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biol. Chem., 2008, 389(11), 1399-1407.
117. Weigert, A.; Weis, N.; Brune, B. Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology, 2009, 214(9-10), 748-760.
118. Abuhusain, H. J.; Matin, A.; Qiao, Q.; Shen, H.; Kain, N.; Day, B. W.; Stringer, B. W.; Daniels, B.; Laaksonen, M. A.; Teo, C.; McDonald, K. L.; Don, A. S. A metabolic shift favouring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J. Biol. Chem., 2013, 288(52), 37355-37364.
119. Wallington-Beddoe, C. T.; Powell, J. A.; Tong, D.; Pitson, S. M.; Bradstock, K. F.; Bendall, L. J. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression Cancer Res., 2014, 74(10), 2803-2815.
120. Bektas, M.; Jolly, P. S.; Muller, C.; Eberle, J.; Spiegel, S.; Geilen, CC. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene, 2005, 24(1), 178-187.
121. Davis, M. D.; Clemens, J. J.; Macdonald, T. L.; Lynch, K. R. Sphingosine-1-phosphate analogs as receptor antagonists. J. Biol. Chem., 2005, 280(11), 9833-9841.
122. Brizuela, L.; Martin, C.; Jeannot, P.; Ader, I.; Gstalder, C.; Andrieu, G.; Bocquet, M.; Laffosse, J. M.; Gomez-Brouchet, A.; Malavaud, B.; Sabbadini, R. A.; Cuvillier, O. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol. Oncol., 2014, 8(7), 1181-1195.
123. Le Scolan, E.; Pchejetski, D.; Banno, Y.; Denis, N.; Mayeux, P.; Vainchenker, W.; Levade, T.; Moreau-Gachelin F. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood, 2005, 106(5), 1808-1816.
124. Nava, V. E.; Cuvillier, O.; Edsall, L. C.; Kimura, K.; Milstien, S.; Gelmann, E. P.; Spiegel, S. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res., 2000, 60(16), 4468-4474.
125. Baran, Y.; Salas, A.; Senkal, C. E.; Gunduz, U.; Bielawski, J.; Obeid, L. M.; Ogretmen, B. Alterations of ceramide/sphingosine-1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282(15), 10922-10934.
126. Marfe, G.; Di Stefano, C.; Gambacurta, A.; Ottone, T.; Martini, V.; Abruzzese, E.; Mologni, L.; Sinibaldi-Salimei, P.; de Fabritis, P.; Gambacorti-Passerini, C.; Amadori, S.; Birge R. B. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp. Hematol., 2011, 39(6), 653-665.
127. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117(9), 2408-2421.
128. Tonelli, F.; Lim, K. G.; Loveridge, C.; Long, J.; Pitson, S. M.; Tigyi, G.; Bittman, R.; Pyne, S.; Pyne, N. J. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell. Signal., 2010, 22(10), 1536-1542.
129. Sukocheva, O.; Wang, L.; Verrier, E.; Vadas, M. A.; Xia, P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology, 2009, 150(10), 4484-449.
130. Rosa, R.; Marciano, R.; Malapelle, U.; Formisano, L.; Nappi, L.; D'Amato, C.; D'Amato, V.; Damiano, V.; Marfè, G.; Del Vecchio, S.; Zannetti, A.; Greco, A.; De Stefano, A.; Carlomagno, C.; Veneziani, B. M.; Troncone, G.; De Placido, S.; Bianco, R. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin. Cancer Res., 2013, 19(1), 138-147.
131. Antoon, J. W.; White, M. D.; Burow, M. E.; Beckman, B. S. Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncol. Rep., 2012, 27(6), 1779-1786.
132. Beljanski, V.; Knaak, C.; Zhuang, Y.; Smith, C. D. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs, 2011, 29(6), 1132-1142.
133. Anelli, V.; Gault, C. R.; Cheng, A. B.; Obeid, L. M. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J. Biol Chem., 2008, 283(6), 3365-3375.
134. Cho, S. Y.; Lee, H. J.; Jeong, S. J.; Kim, H. S.; Chen, C. Y.; Lee, E. O.; Kim, S. H. Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1alpha inactivation in hypoxic PC-3 prostate cancer cells. J. Pineal Res., 2011, 51(1), 87-93.
135. Schnitzer, S. E.; Weigert, A.; Zhou, J.; Brune, B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol. Cancer Res., 2009, 7(3), 393-401.
136. Herr, B.; Zhou, J.; Werno, C.; Menrad, H.; Namgaladze, D.; Weigert, A.; Dehne, N.; Brüne, B. The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1alpha in macrophages via sphingosine-1-phosphate and transforming growth factor-beta. Blood, 2009, 114(10), 2140-2148.
137. Visentin, B.; Vekich, J. A.; Sibbald, B. J.; Cavalli, A. L.; Moreno, K. M.; Matteo, R. G.; Garland, W. A.; Lu, Y.; Yu, S.; Hall, H. S.; Kundra, V.; Mills, G. B.; Sabbadini, R. A. Validation of an antisphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 2006, 9(3), 225-238.
138. Chae, S. S.; Paik, J. H.; Furneaux, H.; Hla, T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest., 2005, 114(8), 1082-1089.
139. Jiang, Y.; Divittore, N. A.; Young, M. M.; Jia, Z.; Xie, K.; Ritty, T. M.; Kester, M.; Fox, T. E. Altered sphingolipid metabolism in patients with metastatic pancreatic cancer. Biomolecules, 2013, 3(3), 435-448.
140. Nagahashi, M.; Ramachandran, S.; Kim, E. Y.; Allegood, J. C.; Rashid, O. M.; Yamada, A.; Zhao, R.; Milstien, S.; Zhou, H.; Spiegel, S.; Takabe, K. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res., 2012, 72(3), 726-735.
141. Sutphen, R.; Xu, Y.; Wilbanks, G. D.; Fiorica, J.; Grendys, E. C., Jr.; LaPolla, J. P.; Arango, H.; Hoffman, M. S.; Martino, M.; Wakeley, K.; Griffin, D. Blanco, R. W. Cantor, A. B. Xiao, Y. J.; Krischer, J. P. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 2004, 13(7), 1185-1191.
142. Schwab, S. R.; Pereira, J. P.; Matloubian, M.; Xu, Y.; Huang, Y.; Cyster, J. G. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science, 2005, 309(5741), 1735-1739.
143. Pappu, R.; Schwab, S. R.; Cornelissen, I.; Pereira, J. P.; Regard, J. B.; Xu, Y.; Camerer, E.; Zheng, Y. W.; Huang, Y.; Cyster, J. G.; Coughlin, S. R. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science, 2007, 316(5822), 295-298.
144. Nunes, J.; Naymark, M.; Sauer, L.; Muhammad, A.; Keun, H.; Sturge, J.; Stebbing, J.; Waxman, J.; Pchejetski, D. Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection. Br. J. Cancer., 2012, 106(5), 909-915.
145. Zhang, L.; Wang, X.; Bullock, A. J.; Callea, M.; Shah, H.; Song, J.; Moreno, K.; Visentin, B.; Deutschman, D.; Alsop, D. C.; Atkins, M. B.; Mier, J. W.; Signoretti, S.; Bhasin, M. K.; Sabbadini, R. A.; Bhatt, R. S. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer Clin. Cancer Res., 2015 Jan 14. pii: clincanres. 2031. 2014. [Epub ahead of print].
146. Yatomi, Y.; Ruan, F.; Megidish, T.; Toyokuni, T.; Hakomori, S.; Igarashi, Y. N, N dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry, 1996, 35(2), 626-633.
147. Edsall, L. C.; Van Brocklyn, J. R.; Cuvillier, O.; Kleuser, B.; Spiegel, S. N, N dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry, 1998, 37(37), 12892-12898.
148. Pitson, S. M.; D'Andrea, R. J.; Vandeleur, L.; Moretti, P. A.; Xia, P.; Gamble, J. R.; Vadas, M. A.; Wattenberg, B. W. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem. J., 2000, 350 Pt 2, 429-441.
149. Kono, K.; Sugiura, M.; Kohama, T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J. Antibiot. (Tokyo), 2002, 55(1), 99-103.
150. Tonelli, F.; Alossaimi, M.; Williamson, L.; Tate, R. J.; Watson, D. G.; Chan, E.; Bittman, R.; Pyne, N. J.; Pyne, S. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stressdependent mechanism. Br. J. Pharmacol., 2013, 168(6), 1497-1505.
151. Endo, K.; Igarashi, Y.; Nisar, M.; Zhou, Q. H.; Hakomori, S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N, N-dimethyl and N, N, N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res., 1991, 51(6), 1613-1618.
152. Sweeney, E. A.; Sakakura, C.; Shirahama, T.; Masamune, A.; Ohta, H.; Hakomori, S.; Igarashi, Y. Sphingosine and its methylated derivative N, N-dimethylsphingosine(DMS) induce apoptosis in a variety of human cancer cell lines. Int. J. Cancer, 1996, 66(3), 358-366.
153. Olivera, A.; Kohama, T.; Edsall, L.; Nava, V.; Cuvillier, O.; Poulton, S.; Spiegel, S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Bio., 1999, 147(3), 545-558.
154. Cuvillier, O. Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin. Ther. Targets, 2008, 12(8), 1009-1020.
155. Merrill, A. H.; Jr.; Schmelz, E. M.; Dillehay, D. L.; Spiegel, S.; Shayman, J. A.; Schroeder, J. J; Riley, R. T.; Voss, K. A.; Wang, E. Sphingolipids-The enigmatic lipid class: Biochemistry, physiology, and pathophysiology. Toxicol. Applied Pharmacol., 1997, 142(1), 208-225.
156. Bu, S.; Yamanaka, M.; Pei, H.; Bielawska, A.; Bielawski, J.; Hannun, Y. A.; Obeid, L.; Trojanowska, M. Dihydrosphingosine Iphosphate stimulates MMP1 gene expression via activation of ERK1/2-Etsl pathway in human fibroblasts. Faseb J., 2006, 20(1), 184-186.
157. Sachs, C. W.; Safa, A. R.; Harrison, S. D.; Fine, R. L. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J. Biol. Chem., 1995, 270(44), 26639-26648.
158. Coward, J.; Ambrosini, G.; Musi, E.; Truman, J. P.; Haimovitz-Friedman, A.; Allegood, J. C.; Wang, E.; Merrill, A. H. Jr.; Schwartz, G. K. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy, 2009, 5(2), 184-193.
159. Dickson, M. A.; Carvajal, R. D.; Merrill, A. H. Jr.; Gonen, M.; Cane, L. M.; Schwartz, G. K. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res., 2011, 17(8), 2484-2492.
160. Leroux, M. E.; Auzenne, E.; Evans, R.; Hail, N., Jr.; Spohn, W.; Ghosh, S. C.; Farquhar, D.; McDonnell, T.; Klostergaard, J. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. The Prostate, 2007, 67(5), 1699-1717.
161. Loveridge, C.; Tonelli, F.; Leclercq, T.; Lim, K. G.; Long, J. S., Berdyshev, E.; Tate, R. J.; Natarajan, V.; Pitson, S. M.; Pyne, N. J.; Pyne, S. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem., 2010, 285(50), 38841-3852.
162. French, K.; Upson, J.; Keller, S.; Zhuang, Y.; Yun, J.; Smith, C. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exper. Ther., 2006, 318(2), 596-603.
163. Li, P. H.; Wu, J. X.; Zheng, J. N.; Pei, D. S. A sphingosine kinase-1 inhibitor, SKI-II, induces growth inhibition and apoptosis in human gastric cancer cells. Asian Pac. J. Cancer Prev., 2014, 15(23), 10381-10385.
164. Zhang, C.; He, H.; Zhang, H.; Yu, D.; Zhao, W.; Chen, Y.; Shao, R. The blockage of Ras/ERK pathway augments the sensitivity of SphK1 inhibitor SKI II in human hepatoma HepG2 cells. Biochem. Biophys. Res. Commun., 2013, 434(1), 35-41.
165. Graler, M. H.; Goetzl, E. J. The immunosuppressant FTY720 downregulates sphingosine 1-phosphate G-protein-coupled receptors. Faseb J., 2004, 18(3), 551-553.
166. Kiuchi, M.; Adachi, K.; Kohara, T.; Teshima, K.; Masubuchi, Y.; Mishina, T.; Fujita, T. Synthesis and biological evaluation of 2, 2-disubstituted 2-aminoethanols: analogues of FTY720. Bioorg. Med. Chem. Lett., 1998, 8(1), 101-106.
167. Permpongkosol, S.; Wang, J. D.; Takahara, S.; Matsumiya, K.; Nonomura, N.; Nishimura, K.; Tsujimura, A.; Kongkanand, A.; Okuyama, A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: Modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Intl. J. Cancer, 2002, 98(2), 167-172.
168. Wang, J. D.; Takahara, S.; Nonomura, N.; Ichimaru, N.; Toki, K.; Azuma, H.; Matsumiya, K.; Okuyama, A.; Suzuki, S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. The Prostate, 1999, 40(1), 50-55.
169. Zhang, L.; Wang, H. D.; Ji, X. J.; Cong, Z. X.; Zhu, J. H.; Zhou, Y. FTY720 for cancer therapy (Review). Oncol. Rep., 2013, 30, 2571-2578.
170. Liu, Q.; Zhao, X.; Frissora, F.; Ma, Y.; Santhanam, R.; Jarjoura, D.; Lehman, A.; Perrotti, D.; Chen, C. S.; Dalton, J. T.; Muthusamy, N.; Byrd, J. C. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 2008, 111(1), 275-284.
171. Wallington-Beddoe, C. T.; Hewson, J.; Bradstock, K. F.; Bendall, L. J. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy, 2011, 7(7), 707-715.
172. Liao, A.; Hu, R.; Zhao, Q.; Li, J.; Li, Y.; Yao, K.; Zhang, R.; Wang, H.; Yang, W.; Liu, Z. Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur. J. Pharm. Sci., 2012, 45(5), 600-605.
173. Alinari, L.; Baiocchi, R. A.; Praetorius-Ibba, M. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? Autophagy, 2012, 8(3), 416-417.
174. Alinari, L.; Mahoney, E.; Patton, J.; Zhang, X.; Huynh, L.; Earl, C. T.; Mani, R.; Mao, Y.; Yu, B.; Quinion, C.; Towns, W. H.; Chen, C. S.; Goldenberg, D. M.; Blum, K. A.; Byrd, J. C.; Muthusamy, N.; Praetorius-Ibba, M.; Baiocchi, R. A. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood, 2011, 118(26), 6893-6903.
175. Liu, Q.; Alinari, L.; Chen, C. S.; Yan, F.; Dalton, J. T.; Lapalombella, R.; Zhang, X.; Mani, R.; Lin, T.; Byrd, J. C.; Baiocchi, R. A.; Muthusamy, N. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin. Cancer Res., 2010, 16(12), 3182-3192.
176. Roberts, K. G.; Smith, A. M.; McDougall, F.; Carpenter, H.; Horan, M.; Neviani, P.; Powell, J. A.; Thomas, D.; Guthridge, M. A.; Perrotti, D.; Sim, A. T.; Ashman, L. K.; Verrills, N. M. Essential requirement for PP2A inhibition by the oncogenic receptor c-KITsuggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res., 2010, 70(13), 5438-5447.
177. Ubai, T.; Azuma, H.; Kotake, Y.; Inamoto, T.; Takahara, K.; Ito, Y.; Kiyama, S.; Sakamoto, T.; Horie, S.; Muto, S.; Takahara, S.; Otsuki, Y.; Katsuoka, Y. FTY720 induced Bcl-associated and Fasindependent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res., 2007, 27(1A), 75-88.
178. LaMontagne, K.; Littlewood-Evans, A.; Schnell, C.; O'Reilly, T.; Wyder, L.; Sanchez, T.; Probst, B.; Butler, J.; Wood, A.; Liau, G.; Billy, E.; Theuer, A.; Hla, T.; Wood. J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res., 2006, 66(1), 221-231.
179. Payne, S. G.; Oskeritzian, C. A.; Griffiths, R.; Subramanian, P.; Barbour, S. E.; Chalfant, C.; Milstien, S.; Spiegel, S. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 2007, 109(83), 1077-1085.
180. Ho, J. W.; Man, K.; Sun, C. K.; Lee, T. K.; Poon, R. T.; Fan, S. T. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther., 2005, 4(9), 1430-1438.
181. Lee, T. K.; Man, K.; Ho, J. W.; Wang, X. H.; Poon, R. T.; Xu, Y.; Ng, K. T.; Chu, A. C.; Sun, C. K.; Ng, I. O.; Sun, H. C.; Tang, Z. Y.; Xu, R.; Fan, S. T. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res., 2005, 11(23), 8458-8466.
182. Paugh, S. W.; Paugh, B. S.; Rahmani, M.; Kapitonov, D.; Almenara, J. A.; Kordula, T.; Milstien, S.; Adams, J. K.; Zipkin, R. E.; Grant, S.; Spiegel, S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood, 2008, 112(4), 1382-1391.
183. Watson, D. G.; Tonelli, F.; Alossaimi, M.; Williamson, L.; Chan, E.; Gorshkova, I.; Berdyshev, E.; Bittman, R.; Pyne, N. J.; Pyne, S. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell. Signal., 2013, 25(4), 1011-1017.
184. Kennedy, A. J.; Mathews, T. P.; Kharel, Y.; Field, S. D.; Moyer, M. L.; East, J. E.; Houck, J. D.; Lynch, K. R.; Macdonald, T. L. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J. Med. Chem., 2011, 54(10), 3524-3548.
185. Hengst, J.; Wang, X.; Sk, U.; Sharma, A.; Amin, S.; Yun, J. Development of a Sphingosine Kinase 1 Specific Small-Molecule Inhibitor. Bioorg. Med. Chem. Lett., 2010, 20(24), 7498-7502.
186. Vogt, D.; Weber, J.; Ihlefeld, K.; Brüggerhoff, A.; Proschak, E.; Stark, H. Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors. Bioorg. Med. Chem., 2014, 22(19), 5354-5367.
187. Sharma, A. K. Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). Exp. Opin. Ther. Pat., 2011, 21(5), 807-812.
188. Hazar-Rethinam, M.; de Long. L. M.; Gannon, O. M.; Topkas, E.; Boros, S.; Vargas, A. C.; Dzienis, M.; Mukhopadhyay, P.; Simpson, F.; Endo-Munoz, L.; Saunders, N. A. A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cel l Carcinoma. Clin. Cancer Res., 2015, 21(2), 417-427.
189. Lim, K. G.; Sun, C.; Bittman, R.; Pyne, N. J.; Pyne, S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell. Signal., 2011, 23(10), 1590-1595.
190. French, K. J.; Zhuang, Y.; Maines, L. W.; Gao, P.; Wang, W.; Beljanski, V.; Upson, J. J.; Green, C. L.; Keller, S. N.; Smith, C. D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther., 2010, 333(1), 129-139.
191. Antoon, J. W.; White, M. D.; Meacham, W. D.; Slaughter, E. M.; Muir, S. E.; Elliott, S.; Rhodes, L. V.; Ashe, H. B.; Wiese, T. E.; Smith, C. D.; Burow, M. E.; Beckman, B. S. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology, 2010, 151(11), 5124-5135.
192. Chumanevich, A. A.; Poudyal, D.; Cui, X.; Davis, T.; Wood, P. A.; Smith, C. D.; Hofseth, L. J. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis, 2010, 31(10), 1787-1793.
193. Beljanski, V.; Knaak, C.; Zhuang, Y.; Smith, C. D. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest. New Drugs, 2011, 29(6), 1132-1142.
194. Beljanski, V.; Lewis, C. S.; Smith, C. D. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol. Ther. 2011, 11(5), 524-534.
195. Gao, P.; Peterson, Y. K.; Smith, R. A.; Smith, C. D. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One, 2012, 7(9), e44543.
196. Antoon, J. W.; White, M. D.; Slaughter, E. M.; Driver, J. L.; Khalili, H. S.; Elliott, S.; Smith, C. D.; Burow, M. E.; Beckman B. S. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol. Ther., 2011, 11(7), 678-689.
197. Antoon, J. W.; White, M. D.; Driver, J. L.; Burow, M. E.; Beckman, B. S. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp. Biol. Med., 2012, 237(7), 832-844.
198. Gestaut, M. M.; Antoon, J. W.; Burow, M. E.; Beckman, B. S. Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacol. Rep., 2014, 66(1), 174-178.
199. Kharel, Y.; Raje, M.; Gao, M.; Gellett, A. M.; Tomsig, J. L.; Lynch, K. R.; Santos, W. L. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem. J., 2012, 447(1), 149-157.
200. Olivera, A.; Mizugishi, K.; Tikhonova, A.; Ciaccia, L.; Odom, S.; Proia, R. L.; Rivera, J. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity, 2007, 26(3), 287-297.
201. Zemann, B.; Kinzel, B.; Muller, M.; Reuschel, R.; Mechtcheriakova, D.; Urtz, N.; Bornancin, F.; Baumruker, T.; Billich, A. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood, 2006, 107(4), 1454-1458.
202. Raje, M. R.; Knott, K.; Kharel.; Y, Bissel, P.; Lynch, K. R.; Santos, W. L. Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. Bioorg. Med. Chem., 2012, 20(1), 183-194.
203. Liu, K.; Guo, T. L.; Hait, N. C.; Allegood, J.; Parikh, H. I. Xu, W.; Kellogg, G. E.; Grant, S.; Spiegel, S.; Zhang, S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2, 4-dione(K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One, 2013, 8(2), e56471.
204. Kim, J. W.; Kim, Y. W., Inagaki, Y.; Hwang, Y. A.; Mitsutake, S.; Ryu, Y. W.; Lee, W. K.; Ha, H. J.; Park, C. S.; Igarashi, Y. Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg. Med. Chem., 2005, 13(10), 3475-3485.
205. Hara-Yokoyama, M.; Terasawa, K.; Ichinose, S.; Watanabe, A.; Podyma-Inoue, K. A.; Akiyoshi, K.; Igarashi, Y.; Yanagishita, M. (2013) Sphingosine kinase 2 inhibitor SG-12 induces apoptosis via phosphorylation by sphingosine kinase 2. Bioorg. Med. Chem. Lett., 2013, 23(7), 2220-2224.
206. Xiao, M.; Liu, Y. G.; Zou, F. Sensitization of human colon cancer cells to sodium butyrate-induced apoptosis by modulation on of sphingosine kinase 2 and protein kinase D. Exp. Cell Res., 2012, 318(1), 43-52.
207. Xiao, M.; Liu, Y. G.; Zou, M. C.; Zou, F. Sodium butyrate induces apoptosis of human colon cancer cells by modulating ERK and sphingosine kinase 2. Biomed. Environ. Sci., 2014, 27(3), 197-203.
208. Patwardhan, N. N.; Morris, E.; Kharel, Y.; Raje, M.; Gao, M.; Tomsig, J.; Lynch, K. R.; Santos, W. L. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: Discovery of SphK 1 and 2 selective inhibitors. J. Med. Chem., 2015, Feb 2.
209. Rex, K.; Jeffries, S.; Brown, M. L.; Carlson, T., Coxon, A.; Fajardo, F.; Frank, B.; Gustin, D., Kamb, A.; Kassner, P. D.; Li, S.; Li, Y.; Morgenstern, K.; Plant, M.; Quon, K., Ruefli-Brasse, A.; Schmidt, J.; Swearingen, E.; Walker, N.; Wang, Z.; Watson, J. E.; Wickramasinghe, D., Wong, M., Xu, G.; Wesche, H. Sphingosine kinase activity is not required for tumor cell viability. PLoS One, 2013, 8(7), e68328.
210. O'Brien, N.; Jones, S. T.; Williams, D. G.; Cunningham, H. B.; Moreno, K.; Visentin, B.; Gentile, A.; Vekich, J.; Shestowsky, W.; Hiraiwa, M.; Matteo, R.; Cavalli, A.; Grotjahn. D.; Grant, M.; Hansen, G.; Campbell, M. A.; Sabbadini, R. Production and characterization of monoclonal anti-sphingosine-l-phosphate antibodies. J. Lipid Res., 2009, 50(11), 2245-2257.
211. Ponnusamy, S.; Selvam, S. P.; Mehrotra, S.; Kawamori, T.; Snider, A. J.; Obeid, L. M.; Shao, Y.; Sabbadini, R.; Ogretmen, B. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol. Med., 2012, 4(8), 761-775.